NB9

NB9 (also NB-9 or NB9) is a cancer cell line derived from a human neuroblastoma, a solid tumor that affects the sympathetic nervous system. Neuroblastoma most often originates from the adrenal medulla or sympathetic chain and is most common in children. NB9 was developed from the primary tumor tissue of a 5-year-old female neuroblastoma patient. NB9 is tumorigenic and immortalized. NB9, like other neuroblastoma-derived cell lines, has the potential to display variable morphology and expression of tumor-associated genes. NB9 is frequently used to study neuroblastoma pathogenesis and development. NB9 has been used in several studies published on the genetics behind neuroblastic diseases including RAS-related and other oncogenic mutations. NB9 cells may be cultured under typical mammalian tissue culture conditions and maintained in serum-supplemented media (e.g. RPMI-1640 with fetal bovine serum). NB9 cells have properties that allow them to be cultured in suspension or as an adherent monolayer, depending on the application. This cell line is a model for drug screening and pharmacologic testing, genetic perturbation, signaling studies, and other applications related to the study of pediatric neuroblastoma and putative therapeutic interventions.